In this article:

H.C. Wainwright Reaffirms Their Buy Rating on AKOUOS (AKUS)

In this article:
In this article:

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on AKOUOS (AKUSResearch Report) today and set a price target of $25.00. The company’s shares closed last Monday at $5.81, close to its 52-week low of $5.30.

According to TipRanks.com, Pantginis is ranked 0 out of 5 stars with an average return of -17.6% and a 23.8% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Actinium Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for AKOUOS with a $25.00 average price target.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $22.88 and a one-year low of $5.30. Currently, AKOUOS has an average volume of 131.9K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Akouos Inc is a genetic medicine company focused on developing gene therapies that restore, improve, and preserve hearing. The company is involved in developing potential genetic medicines for a variety of inner ear disorders.

Read More on AKUS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed

In this article:

Latest News Feed